Senseonics reported third-quarter 2025 revenue of $8.1 million, up 90% year over year, as U.S. new patient starts jumped 160% and the company returned to positive gross profit on the back of its 365-day implantable CGM. The company is preparing to take back commercial responsibility for Eversense from Ascensia Diabetes Care under a signed memorandum of understanding, expand direct-to-consumer marketing to record lead volumes, execute a 1-for-20 reverse stock split, and plans to transfer its listing to the Nasdaq Global Market on November 17. Management reiterated expectations for roughly $35 million in 2025 revenue, a doubling of the global patient base, and further margin expansion, while targeting CE mark for Eversense 365 by year-end with an EU launch in the first half of 2026 and an IDE submission for its next-generation Gemini sensor by year-end.
The strategic pivot is clear: Senseonics is moving from a distributor-dependent model to owning the go-to-market engine for an implantable CGM that competes on longevity and user experience rather than sheer scale. The question for commercial leaders is whether a focused medtech can build a high-touch field force, activate enough procedure-capable sites, and convert DTC demand into sustained reinsertions without overextending cash. The company’s claim that most new users are switching from other CGMs suggests the offer resonates with dissatisfied incumbents’ patients, but displacing entrenched brands requires flawless execution at the point of care and payer-aligned economics.
This matters now because the CGM market is widening beyond intensively managed type 1 diabetes into basal-only type 2 and cardiometabolic risk management, where adherence and wearability are decisive. A 365-day implant reduces weekly or biweekly sensor churn, on-body burden, and supply logistics, which could translate into better persistence and fewer data gaps. For patients with skin sensitivities or device fatigue, the implantable profile is differentiated. For HCPs, the model introduces a minor surgical procedure, training, and scheduling, offset by potential procedure reimbursement and a stickier patient relationship. For payers, the calculus shifts from frequent disposables to an annual insertion plus transmitter, putting pressure on Senseonics to deliver real-world evidence on hypoglycemia reduction, time-in-range improvements, and net utilization savings that justify coverage at parity or better with transcutaneous systems.
The move to internalize commercialization mirrors a broader medtech trend: companies reclaiming channel control once product-market fit emerges to tighten pricing, contracting, and demand generation. It also raises transition risk. Channel handoffs can depress near-term sales if provider onboarding, inventory flows, or patient support are not seamless. The heavy DTC spend that drove lead generation must now be matched by local site activation, referral routing, and payer adjudication to avoid leakage. In Europe, CE mark and national reimbursement dynamics will determine whether an implantable CGM can scale beyond centers of excellence; tender processes and DRG structures will shape economics for hospitals and clinics.
Financially, Senseonics has narrowed losses but remains subscale, guiding to 35–40% gross margins for 2025 and approximately $60 million of operating cash use this year. Liquidity, capital market positioning via Nasdaq, and evidence cadence will set the runway. Competitors are not standing still: Dexcom and Abbott continue to streamline sensors, expand primary care penetration, and integrate with digital ecosystems. Weekly calibration and in-clinic insertion remain friction points Senseonics must neutralize with workflow, training, and patient experience design.
The following year will test whether a procedure-enabled, once-a-year CGM can carve out a durable share against convenience-at-scale incumbents. Watch site activation velocity, conversion rates from DTC leads to insertions, payer mix and coverage breadth, and, critically, 12-month reinsertion rates. If Senseonics can prove superior persistence, fewer therapy interruptions, and lower total cost of care in real-world cohorts, payers and health systems may back an implantable niche that grows. If not, does the company have the field infrastructure and evidence to make implantable CGM more than a compelling alternative for a narrow subset of patients?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
